Vir Biotechnology
224 hedge funds and large institutions have $2.18B invested in Vir Biotechnology in 2022 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 81 increasing their positions, 74 reducing their positions, and 25 closing their positions.
80% more call options, than puts
Call options by funds: $5.69M | Put options by funds: $3.15M
36% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 25
30% more capital invested
Capital invested by funds: $1.68B → $2.18B (+$501M)
2% more funds holding
Funds holding: 220 → 224 (+4)
9% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 74
0.86% less ownership
Funds ownership: 65.52% → 64.66% (-0.86%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$26.9M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$20.8M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$12.1M |
| 4 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
+$10.9M |
| 5 |
BlackRock
New York
|
+$6.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIAU
SB Investment Advisers (UK)
London,
United Kingdom
|
-$44.8M |
| 2 |
Renaissance Technologies
New York
|
-$11.1M |
| 3 |
State Street
Boston,
Massachusetts
|
-$8.68M |
| 4 |
Temasek Holdings
Singapore
|
-$8M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$7.43M |
VIR Hedge Fund Activity: Q4 2022 in Review
224 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q4 2022, worth a combined $2.18B — up 30% from $1.68B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new VIR positions and 25 closed out — a net gain of 9 holders — while 81 added to existing stakes and 74 trimmed.
The largest buyer was Pacer Advisors, adding an estimated $26.9M. The largest seller was SB Investment Advisers (UK), cutting an estimated $44.8M.
- 224 institutional investors held Vir Biotechnology (VIR) as of Q4 2022, up from 220 in Q3 2022.
- Funds reported $2.18B of Vir Biotechnology stock for Q4 2022, up 30% quarter-over-quarter.
- 34 funds opened new Vir Biotechnology positions in Q4 2022 and 25 closed out, a net change of +9 holders.
- The largest Vir Biotechnology buyer in Q4 2022 was Pacer Advisors, an estimated $26.9M added.
- The largest Vir Biotechnology seller in Q4 2022 was SB Investment Advisers (UK), an estimated $44.8M sold.
Based on aggregated 13F filings for Q4 2022.